Editorial commentary: Management of hepatitis C virus in HIV-infected patients in the era of direct-acting antivirals

Clinical Infectious Diseases

Volumn 58, Issue 6, 2014, Pages 880-882

  Zeremski, Marija ^a   Martinez, Anthony D ^a   Talal, Andrew H ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

HCV; HCV treatment; HIV HCV coinfection; viral hepatitis

Indexed keywords

BOCEPREVIR; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; TELAPREVIR; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; DRUG EFFICACY; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; MORBIDITY; NOTE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; COINFECTION; HEPACIVIRUS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; VIROLOGY;

ANTIVIRAL AGENTS; COINFECTION; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS;

EID: 84895762177     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit804     Document Type: Note

References (26)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558-67.
2. Vandelli C, Renzo F, Romano L, et al. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. Am J Gastroenterol 2004; 99:855-9.
3. Bradshaw D, Matthews G, Danta M. Sexually transmitted hepatitis C infection: the new epidemic in MSM? Curr Opin Infect Dis 2013; 26:66-72.
4. Boesecke C, Rockstroh JK. Acute hepatitis C in patients with HIV. Semin Liver Dis 2012; 32:130-7.
5. Taylor LE, Holubar M, Wu K, et al. Incident hepatitis C virus infection among US HIVinfected men enrolled in clinical trials. Clin Infect Dis 2011; 52:812-8.
6. Witt MD, Seaberg EC, Darilay A, et al. Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984-2011. Clin Infect Dis 2013; 57: 77-84.
7. Soriano V, Vispo E, Fernandez-Montero JV, Labarga P, Barreiro P. Update on HIV/HCV coinfection. Curr HIV/AIDS Rep 2013; 10: 226-34.
8. Kim AY, Onofrey S, Church DR. An epidemiologic update on hepatitis C infection in persons living with or at risk of HIV infection. J Infect Dis 2013; 207(suppl 1):S1-6.
9. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
10. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
11. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-9.
12. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-50.
13. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-16.
14. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1207-17.
15. Poordad F,McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
16. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-28.
17. Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013; 159:86-96.
18. Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013; 13: 597-605.
19. Sulkowski M, Rodriguez-Torres M, Lalezari JP, et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1) [abstract 212]. Hepatology 2013; 58 (suppl):313A- 314A.
20. Dieterich D, Rockstroh J, Orkin C, et al. Simeprevir (TMC435) plus peginterferon/ribavirin in patients co-infected with HCV genotype- 1 and HIV-1: primary analysis of the C212 study [abstract LBPS9/50]. In: 14th European AIDS Conference, Brussels, Belgium, 2013. Available at: http://www.professional abstracts.com/eacs2013/planner/index.php? go=abstract&action=abstract- show&absno= 1083&. Accessed 14 November 2013.
21. Rockstroh J, Nelson M, Soriano V, et al. STARTVerso 4 phase III trial of faldaprevir plus peg interferon alpha-2a and ribavirin (PR) in patients with HIV and HCV genotype 1 coinfection: end of treatment response [abstract 1099]. Hepatology 2013; 58(suppl): 741A-742A.
22. Dore GJ, Hellard M, Matthews GV, et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 2010; 138:123-35. e1-2.
23. Deterding K, Gruner N, Buggisch P, et al. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis 2013; 13:497-506.
24. Feld JJ. Treatment indication and response to standard of care with peginterferon and ribavirin in acute and chronic HCV infection. Best Pract Res Clin Gastroenterol 2012; 26:429-44.
25. Boesecke C, Wedemeyer H, Rockstroh JK. Diagnosis and treatment of acute hepatitis C virus infection. Infect Dis Clin North Am 2012; 26:995-1010.
26. Fierer DS, Dieterich DT, Mullen MP, et al. Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. Clin Infect Dis 2014; 58:873-9.